Epix Medical
This article was originally published in The Gray Sheet
Executive Summary
Phase III clinical trials for the AngioMARK (MS-325) injectable MRI contrast imaging agent for peripheral vascular indications are slated to begin in early 1999, Epix President and CEO Mike Webb reports Nov. 30 at the BancBoston Robertson Stephens conference in New York City. Data from Phase II clinicals were presented the same week at the Radiological Society of North America meeting in Chicago. The company expects to file a new drug application with FDA in the first half of 2000, Webb says